0001209191-22-044021.txt : 20220802
0001209191-22-044021.hdr.sgml : 20220802
20220802214202
ACCESSION NUMBER: 0001209191-22-044021
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220729
FILED AS OF DATE: 20220802
DATE AS OF CHANGE: 20220802
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Holtzman Douglas
CENTRAL INDEX KEY: 0001874371
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40655
FILM NUMBER: 221130732
MAIL ADDRESS:
STREET 1: 1616 EASTLAKE AVENUE E.
STREET 2: SUITE 208
CITY: SEATTLE
STATE: WA
ZIP: 98102
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Icosavax, Inc.
CENTRAL INDEX KEY: 0001786255
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1616 EASTLAKE AVE E, SUITE 208
CITY: SEATTLE
STATE: WA
ZIP: 98102
BUSINESS PHONE: (206) 737-0085
MAIL ADDRESS:
STREET 1: 1616 EASTLAKE AVE E, SUITE 208
CITY: SEATTLE
STATE: WA
ZIP: 98102
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-07-29
0
0001786255
Icosavax, Inc.
ICVX
0001874371
Holtzman Douglas
C/O ICOSAVAX, INC.
1930 BOREN AVE., SUITE 1000
SEATTLE
WA
98101
0
1
0
0
Chief Scientific Officer
Common Stock
2022-07-29
4
S
0
585
7.1076
D
303048
D
Common Stock
2022-08-01
4
S
0
9337
6.6374
D
293711
D
Common Stock
2022-08-02
4
S
0
453
6.7038
D
293258
D
Common Stock
2022-02-18
4
G
0
20000
0.00
D
22440
I
By Stanley Holtzman
Represents shares withheld by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person to cover the withholding taxes upon settlement of restricted stock units issued to the Reporting Person.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.93 to $7.75. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Also includes the sale of 7,666 shares effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 16, 2021.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.38 to $7.17. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.460 to $6.865. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Douglas Holtzman, Ph.D. holds power-of-attorney (POA) over the shares owned by Stanley Holtzman. As POA, Dr. Holtzman holds voting and dispositive control over such shares. Dr. Holtzman disclaims beneficial ownership of the shares over which he has POA except to the extent of any pecuniary interest therein.
/s/ Elizabeth Bekiroglu, Attorney-in-Fact
2022-08-02